secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2023-06-21T23:59:59+00:00
Accession:  0001171843-23-004026
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus reports preliminary AB-729 + IFN data at EASL; HBsAg declines seen
--------------------------------------------------------------------------

- Mean HBsAg decline of 1.6 log10 at week 24 during AB-729 lead-in phase.
- 93% of patients (38/41) achieved HBsAg <100 IU/mL during treatment period.
- Four patients reached HBsAg below LLOQ during IFN treatment; no sustained seroclearance yet.
- No serious adverse events, discontinuations, or AB-729-related discontinuations reported.
- Trial ongoing; three patients evaluated to stop NA therapy, one met criteria to stop.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184323004026/0001171843-23-004026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184323004026/f8k_062023.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-004026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer